Gelonghui, April 19丨Huadong Pharmaceutical (000963.SZ) held the 2023 annual performance exchange meeting on April 18, 2024. Regarding “At present, the company has achieved full coverage of small oral molecules, biopharmaceuticals and topical dosage forms in the field of self-immunity. What are the highlights of the company's indication layout in the field of self-immunity for the next 2-3 years?” The company replied that autoimmunity involves many diseases. Currently, the company is paying more attention to rheumatism and skin medications, including ARCALYST, QX001S, PRV-3279, ZORYVE cream and foam, and Wynzora? A variety of products have been laid out, including creams, etc., as well as Enley and Shang Jie, which are strategic partnerships between the company and Pfizer.
In the future, the company's autoimmunity division will continue to expand indications horizontally and vertically in terms of rheumatology and skin medication, and further expand its layout on the basis of introduction+self-research.